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resumo 
 
 
A demência é uma das principais causas de incapacidade entre os idosos, 
afetando mais de 36 milhões de pessoas em todo o mundo. É caracterizada 
pela deterioração progressiva das funções cognitivas, resultando em 
dificuldades no desempenho das atividades diárias do indivíduo. A idade de 
aparecimento dos sintomas, bem como a sua taxa de progressão, são 
variáveis entre a maior parte das demências, sendo estas geralmente 
caracterizadas por uma natureza progressiva, aumentando de gravidade ao 
longo do tempo. Entre os tipos mais frequentes de demência encontram-se a 
Doença de Alzheimer (DA), Demência Vascular, Demência de Corpos de Lewy 
e Demência Frontotemporal. O diagnóstico diferencial das demências é 
realizado tipicamente por testes neuro-psicológicos (para a exclusão de outras 
demências) e por exames imagiológicos. Contudo, muitos dos sintomas 
clínicos característicos podem sobrepor-se entre os diversos tipos de 
demência, o que pode constituir um problema devido a falta de especificidade 
e erros de diagnóstico. A compreensão dos fatores de risco ambientais e 
genéticos que podem modular o aparecimento e/ou progressão de doenças 
abre novas perspetivas relativamente à gestão destas neuropatologias. 
O gene da apolipoproteína E (ApoE) é reconhecido como o maior fator de risco 
na demência, desempenhando um papel central em particular no 
desenvolvimento da DA, sendo que os portadores do alelo ε4 são mais 
suscetíveis para a doença. Além disso, possíveis associações foram também 
propostas entre este gene e outras doenças neurológicas, sendo no entanto 
estes dados ainda controversos. Assim, o objetivo principal deste trabalho 
consistiu em determinar as frequências alélicas e genotípicas do gene ApoE 
num grupo de estudo piloto de pacientes com demência na região de Aveiro. 
Este grupo foi subdividido com base no diagnóstico neuroquímico, no qual 
foram avaliados os níveis de Aβ1-42, Tau-total e fosfo-Tau 181 no líquido 
cefalorraquidiano dos pacientes. Como resultado, observou-se que o alelo ε3 
foi o mais frequente no grupo total, independentemente do tipo de patologia, e 
que o alelo ε2 foi o menos comum. O alelo ε4 foi de facto mais frequente em 
pacientes com DA do que em pacientes com outras neuropatologias, o que 
está de acordo com a relação proposta por outros autores. Adicionalmente, foi 
possível verificar que a frequência deste alelo nos pacientes com patologia 
amilóide é semelhante à observada no grupo DA, sugerindo um papel 
relevante para o ApoE no metabolismo e acumulação cerebral do Aβ. 
Consequentemente, estes indivíduos podem ter uma maior suscetibilidade 
para o desenvolvimento de DA no futuro. Deste modo, os nossos dados 
corroboram a ideia de que o alelo ε4 é um forte fator de risco para a DA e que 
deve ser considerado como um teste genético relevante que pode contribuir 
para o diagnóstico clínico da demência.  
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abstract 
 
Dementia is one of the leading causes of disability among the elderly, affecting 
over 36 million people worldwide. It is characterized by progressive 
deterioration in cognitive functions that impair the successful performance of 
daily living activities. Most forms of dementia are progressive in nature, 
increasing in severity over time, with the rate of symptoms progression and the 
age at onset differing among the major dementing disorders. The most frequent 
types of dementia include Alzheimer´s Disease (AD), Vascular Dementia, 
Dementia of Lewy bodies and Frontotemporal Dementia. Differential diagnosis 
of dementia is typically done by neuropsychological testing (for exclusion of 
other dementias) and neuroimaging investigations. However, many of the 
clinical symptoms typical of dementia may overlap across dementia subtypes, 
which may constitute a diagnosis problem leading to lack of specificity and 
misdiagnosis. Understanding the environmental and genetic factors that 
modulate risks and outcomes of diseases can open new perspectives on the 
management of these neurological disorders. 
Apolipoprotein E gene (ApoE) is recognized as the major genetic risk factor in 
dementia, in particular playing a central role in AD development, being that 
ApoE allele ε4 carriers are more susceptible to disease. Furthermore, putative 
associations have also been proposed between this gene and other 
neurological disorders, nonetheless controversial data have been reported 
regarding these aspect. Hence, the aim of this work was to determine ApoE 
genotypic and allelic frequencies in a pilot study group of dementing patients 
from the catchment area of the “Hospital de São Sebastião” in “Santa Maria da 
Feira”. This group was subdivided according to their neurochemical-based 
diagnosis of dementia, in which Aβ1-42, phospho-Tau 181 and total-Tau levels in 
patients’ cerebrospinal fluid were evaluated. In this study, we could observe 
that allele ε3 was the most frequent in the total study group, independent of the 
type of pathology, and that allele ε2 was the less frequent. Allele ε4 was in fact 
more frequent in AD patients than in other neurological disease patients, in 
agreement with the proposed link established by other authors. Additionally, we 
also find that allele ε4 frequency in patients suffering from amyloid pathology is 
similar to that observed in AD group, suggesting a role for ApoE in Aβ 
metabolism and brain accumulation. Potentially, these patients have a higher 
susceptibility to develop AD pathology in the future. Thus, our data supports the 
idea that ApoE allele ε4 is a strong risk factor for AD development and that it 
may be considered as a relevant genetic test that may assist in the clinical 
diagnosis of dementia. 
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ABBREVIATIONS 
AD Alzheimer´s Disease 
APOE Apolipoprotein E 
APP Amyloid Precursor Protein  
ARD Alcohol Related Dementia 
Aβ Amyloid-β peptide 
BBB Blood-brain Barrier  
CADASIL Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and 
Leukencephalopathy 
CHMP2B Chromatin Modifying Protein 2B 
CNS Central Nervous System  
CSF Cerebrospinal Fluid  
CT Computerized Tomography  
DLB Dementia of Lewy Bodies 
DNA Deoxyribonucleic Acid 
dsDNA Double-stranded DNA  
EDTA Ethylenediamine Tetra-acetic Acid 
ELISA Enzyme-linked Immunoabsorbent Assay 
ER Enzymatic Restriction 
EtBr Ethidium Bromide 
FTD Frontotemporal Dementia 
FTLD Frontotemporal Lobar Degeneration 
FTLD-FUS FTLD with FUS-positive inclusions 
FTLD-τ  FTLD with Tau-positive inclusions 
FTLD-TDP FTLD with TDP-43 positive inclusions 
FTLD-U FTLD with Ubiquitin-positive inclusions 
FTLD-UPS FTLD with UPS components positive inclusions 
FUS Fused in Sarcoma protein 
HD Huntington’s Disease 
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HTT Huntingtin 
gDNA Genomic DNA 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
LBs Lewy Bodies  
LB Loading Buffer 
LRRK2 Leucine-rich Repeat Kinase 2 
MAPT Microtubule-associated Protein Tau 
MCI Mild Cognitive Impairment 
MD Mixed Dementia 
MID Multi-infarct Dementia  
MMSE Mini-mental State Examination  
MRI Magnetic Resonance Imaging 
MTHFR Methylenetetrahydrofolate Reductase 
NFL Neurofilament Light protein  
NFTs Neurofibrillary Tangles 
NOTCH3 Neurogenic locus notch homolog protein 3 
PCR Polymerase Chain Reaction 
PD Parkinson’s Disease 
PET Positron Emission Tomography 
PGRN Progranulin 
PSEN1 Presenilin 1 
PSEN2 Presenilin 2 
P-Tau 181 Phospho-Tau 181 
SNCA α-Synuclein 
SPECT Single Photon Emission Computerized Tomography  
SPs Senile Plaques 
TAE Tris-Acetate-EDTA 
TBE Tris-Borate-EDTA 
TMEM106B Transmembrane protein 106B 
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TDP-43 Transactive response-DNA binding protein-43 
T-Tau Total-Tau 
UPS Ubiquitin-proteasome System 
VaD Vascular Dementia 
VCP Valosin-containing Protein  
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1.1. DEMENTIA, RECOGNIZED AS A MULTIFACTORIAL SYNDROME 
Dementia, a syndrome usually associated with many causes, is characterized by a 
progressive loss of intellectual and cognitive functions that impairs the successful 
performance of daily living activities. It is most frequent in the developed world and is 
becoming even more so as a consequence of life span increase, thus contributing to an 
augmented risk of the elderly population suffering from dementia. Among the clinical 
symptoms, memory is the most common cognitive ability lost with dementia, affecting 
10% of persons aged over 70 years and 20-40% of individuals aged over 85 years. In 
addition to memory, other mental faculties are also affected, such as language, 
visuospatial ability, calculation, judgment and problem solving. Neuropsychiatric and 
behavioral alterations are also present in many cases of dementia, resulting in 
depression, agitation, insomnia, hallucinations and disinhibition (Bird and Miller, 2010). 
Treatment is generally supportive or directed at relieving symptoms, and is usually far 
from perfect. Dementia is now an area of intense scientific study, which brings the 
perspective of more effective therapies and adequate treatments for the different 
dementias types in the future.  
Recognizing dementia is easy if clinical symptoms are severe, which are normally 
associated with the late stages of disease. However, it is much harder to distinguish early 
dementia from the forgetfulness due to anxiety or from the mild cognitive impairment 
(MCI), that often accompanies ageing (usually affecting memory for names and recent 
events), and does not necessarily progress to more severe disability (Wilkinson and 
Lennox, 2005). Also, alterations of multiple capacities usually distinguish dementia from 
other disorders, such as amnesia and aphasia, which affect a single functional domain 
(memory and language, respectively). 
Most forms of dementia are progressive in nature, increasing in severity over time. 
The age of onset and the progression rate of symptoms differ among the major 
dementing disorders. Most have an insidious onset and develop slowly, sometimes over a 
period of many years, even before clinical manifestation of the symptoms. These include 
pathologies such as Alzheimer’s disease (AD), Huntington’s disease (HD) and 
frontotemporal dementia (FTD). Vascular dementia (VaD) follows another pattern of 
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decline: initial cognitive symptoms develop acutely, but in this case the clinical course 
typically proceeds in a stepwise fashion over many years, with periods of relative stability 
punctuated by abrupt deterioration (Squire et al., 2008). 
 In Europe, 7,3 million citizens suffer from dementing disorders and in Portugal over 
153.000 people are affected. As life span is increasing, specialists predict that this value 
will duplicate in 2040 (http://www.alzheimerportugal.org). Presently, estimates indicate 
that there are nearly 36 million people with dementia worldwide 
(http://alzheimers.org.uk). Approximately 1% of the population is affected at age of 60-65 
years, rising to 10–35% in those over 85 years old. Of the patients with late onset 
dementia (>65 years), about half have AD, 16% VaD and 30% other forms of dementia, 
such as dementia with Lewy bodies (DLB) and FTD (Figure 1) (Lobo et al., 2000). In early-
onset cases, AD is relatively less common but it still is the most prevalent cause, while 
FTD, alcohol related dementia and dementia secondary to other diseases (14%), such as 
multiple sclerosis, are relatively more common (Harvey et al., 2003). In particular, for the 
Portuguese population, AD and VaD were also the most common forms of dementia in a 
study realized in rural and urban areas from Northern Portugal (Nunes et al., 2010).  
 
 
 
 
 
 
In the following sections an overview on the molecular and genetic basis of the 
most common forms of dementia will be given, which includes AD, VaD, FTD, DLB, HD and 
alcohol related dementia (ARD). The main clinical characteristics and symptoms will also 
be addressed, demonstrating the disease manifestations overlap and the challenges that 
clinicians have to face to overcome misdiagnosis.  
Figure 1: Major types of late-onset (>65 years) and early-onset (<65 years) dementia. Based on Lobo et al. (2000) and 
Harvey et al. (2003). 
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1.2. MOLECULAR BASIS OF DEMENTIA 
1.2.1. Alzheimer´s Disease  
AD is the most common form of age-related dementia and one of the most serious 
health problems. In Portugal it affects more than 90.000 individuals 
(http://www.alzheimerportugal.org). In the early-onset form of AD, clinical symptoms 
start before 65 years, and is usually caused by hereditary genetic factors (about 5% of all 
AD cases). The most common form is late-onset sporadic AD (>65 years), accounting for 
more than 95% of the cases, which in time is triggered by normal aging 
neurodegeneration and diverse genetic and environmental risk factors. In these forms, 
onset and progression of disease are insidious. Memory is usually affected first, followed 
by language and spatial abilities. After a few years, all aspects of intellectual function are 
affected and the patient may become frail and unsteady, requiring, in general, a full-time 
caregiver.  
 
Neuropathological Hallmarks of AD 
The major pathological hallmarks of AD are the presence of extracellular senile 
plaques and intracellular neurofibrillary tangles, as well as synaptic and neuronal loss, 
namely in the neocortex and hippocampus (Figure 2) (Allsop et al., 1983; Goedert et al., 
1992; Anoop et al., 2010; O'Brien and Wong, 2011), affecting the proper functioning of 
memory and learning processes.  
Figure 2: Brain alterations and histopathological hallmarks in AD. A - Brain cross sections of a healthy person 
(left) and an AD patient (right). From http://wp.stockton.edu/gfb1/tag/alzheimers-disease/. In the latter one, 
an overall shrinkage of the brain tissue is visible, affecting mostly the cerebral cortex, hippocampus and 
amygdala, while ventricles enlarge. B - Senile plaques mainly composed of aggregates of amyloid-β peptides 
(silver stained). C - Neurofibrillary tangles inside the neurons, resulting from Tau protein hyperphosphorylation 
(silver stained). From O’Brien and Wong (2011). 
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Senile Plaques (SPs) are aggregates of amyloid-β peptides (Aβ), which derives from 
the proteolitic cleavage of the Amyloid Precursor Protein (APP), a protein that is produced 
in large quantities in neurons and is metabolized very rapidly (Allsop et al., 1983). APP can 
be cleaved trough the amyloidogenic pathway, producing Aβ, or trough the non-
amyloidogenic pathway, which precludes Aβ formation (Figure 3) (O'Brien and Wong, 
2011). The most common forms of Aβ are constituted by 40 aminoacids (Aβ1-40) or 42 
aminoacids (Aβ1-42). The longer form, Aβ1-42, is less soluble and has a higher propensity to 
aggregate, leading to a greater neurotoxicity relative to Aβ1-40.  All factors that contribute 
to altered APP processing, such as abnormal phosphorylation, oxidative stress and Aβ 
itself, can lead to abnormal Aβ production (Lee et al., 2003; Rebelo et al., 2007; Coma et 
al., 2008; Sodhi et al., 2008; Henriques et al., 2010).  Increased Aβ production and 
accumulation triggers a series of pathogenic processes, such as oxidative stress and 
inflammation, which result in impaired neuronal functions and, consequently, neuronal 
death (Masters et al., 2006; Shen and Kelleher, 2007; Chow et al., 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: APP processing and cleavage products. The non-amyloidogenic APP processing pathway 
(right) involves cleavages by α- and ɤ-secretases, resulting in the generation of a long secreted form of 
APP (sAPPα) and C-terminal fragments (p3 and AICD). The amyloidogenic APP processing pathway 
(left) involves cleavages by β- and ɤ-secretases resulting in the generation of a long secreted form of 
APP (sAPPβ) and C-terminal fragments (Aβ and AICD). Aβ fragments oligomerize and fibrillize leading 
to AD pathology (upper panel). ex- extracellular space, cyt – cytosol. Adapted from Chow et al. (2010). 
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Neurofibrillary tangles (NFTs) are primarily composed of hyperphosphorylated 
form of Tau protein (Goedert et al., 1992). Tau is synthesized within the neuron and 
localized in the axon, where it promotes stability and microtubule assembly, also acting as 
a regulator of intracellular vesicles and organelle traffic, by interaction with cytoskeletal 
proteins, such as actin (Drouet et al., 2000). During AD progression, Tau is 
hyperphosphorylated and subsequently dissociated from microtubules, leading to their 
breakdown in NFTs and paired helical filaments (PHF), which in turn results in neuronal 
degeneration (Sorrentino and Bonavita, 2007).  
Several studies demonstrated that biochemical and pathological alterations 
observed in the AD brain result from abnormal cellular processes such as altered APP 
metabolism, Tau hyperphosphorylation, oxidative stress, inflammation and lipid 
dysregulation (Irizarry, 2004). Currently, one predominant hypothesis for AD 
pathogenesis states that Aβ accumulation in the central nervous system is the first event 
that initiates the pathogenic cascade. According to this hypothesis, increased Aβ 
production and decreased clearance results into Aβ accumulation and aggregation in SPs, 
which in turn interferes with synaptic transmission, activates microglia and stimulates an 
inflammatory response. Consequently, these events lead to neuronal dysfunction, altered 
kinase/phosphatase activity and NFTs formation (Jakob-Roetne and Jacobsen, 2009; 
Karran et al., 2011). This cascade of events will culminate in neuronal death and 
neurodegeneration events. 
 
1.2.2. Vascular Dementia 
 Following AD, Vascular dementia (VaD) is the most common type of dementia and is 
associated with problems in blood circulation to the brain, denominated as 
cerebrovascular disease.  The most common type of VaD is multi-infarct dementia (MID), 
caused by a series of small strokes (which may result in brain tissue death). However, it 
can also be the result of a single major stroke (single-infarct dementia). Individuals who 
have had several strokes may develop chronic cognitive deficits, often in a stepwise 
progression manner, as already mentioned. The occurrence of dementia depends partly 
on the total area of damaged cortex (Bird and Miller, 2010). Strokes usually involve 
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Figure 4: Pathological alterations of VaD. Multi-infarct sites (left); abnormalities 
in subcortical white matter, with multiple areas of abnormal high signal intensity 
(right) (MRI images). From http://dementiatypes.org/Vascular_Dementia.htm 
and Bird and Miller (2010). 
several distinct brain regions, so that clinical features will depend on the location and size 
of vascular lesions. As a consequence, there can be deficits in spatial and executive 
functions, memory, personality changes and also neuropsychiatric manifestations (Kester 
and Scheltens, 2009).  
Another subtype of vascular dementia is CADASIL (cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukencephalopathy), which has a genetic 
component associated with mutations in the NOTCH3 gene, on chromosome 19. This 
disease tends to affect young patients who lack vascular risk factors and the core 
symptoms are recurrent strokes and migraine. (Kester and Scheltens, 2009). 
 
Neuropathological Characteristics of VaD  
If blood vessels in the brain burst (cerebral hemorrhage) or if arteries are blocked 
by plaque formation or clots (thrombosis or embolism), there is insufficient blood flow to 
some parts of the brain and neuronal tissue may die, leading to dementia, depending on 
the brain area affected. The principal risk factors associated with VaD are the same as 
those for heart disease: history of heart attack, atherosclerosis, high cholesterol and 
blood pressure, diabetes and smoking (Pinkston et al., 2009). The more important 
pathological alterations seen in VaD are multiple areas of infarction and, in some patients, 
bilateral abnormalities of subcortical white matter, often occurring in association with 
lacunar infarctions. Examples of such alterations are showed in Figure 4. 
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1.2.3. Dementia with Lewy Bodies 
Dementia with Lewy Bodies (DLB) is a form of dementia that shares clinical and 
histological characteristics with both AD and Parkinson´s Disease (PD). It is characterized 
by fluctuating cognitive impairment, persistent visual hallucinations and parkinsonism. 
Dementia can precede or follow the appearance of parkinsonism. DLB patients are highly 
susceptible to metabolic perturbations, and in some cases the first manifestation of 
illness is delirium, often precipitated by an infection or other systemic disturbance. 
Fluctuations can be marked in DLB patients, with occurrence of episodic confusion mixed 
with lucid intervals (Bird and Miller, 2010).  
 
Neuropathological Hallmarks of DLB 
Pathologically, DLB is characterized by the presence of Lewy Bodies in cortical and 
subcortical regions of the brain, such as limbic system, brainstem and substantia nigra. 
SPs are also present, as well as NFTs, although much less commonly than in AD (Spillantini 
et al., 1998; McKeith et al., 2004; Bird and Miller, 2010).  
Lewy Bodies (LBs) are spherical, intracytoplasmic, eosinophilic neuronal inclusions 
which are mainly constituted by α-synuclein and ubiquitin (Figure 5). Despite major 
efforts, the identification of factors that promote LBs formation and their function in the 
pathological process remain unclear.  When LBs accumulate in large numbers in the brain, 
they may interfere with normal cell function and be associated with abnormalities in 
metabolic processes. The role of intracellular inclusion bodies in neurodegenerative 
disorders has long been controversial; some claiming that inclusions constitute part of the 
pathological process, while others suggest a protective role for them against toxicity 
(Moore et al., 2005; Ross and Poirier, 2005).  
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1.2.4. Frontotemporal Dementia 
FTD is the most common clinical manifestation of Frontotemporal Lobar 
Degeneration (FTLD).  Typically, it is a disease of early onset, and the third most common 
neurodegenerative cause of dementia in patients under the age of 65. In Portugal there is 
no information about the prevalence of this type of dementia, possibly being under-
diagnosed (Guimarães et al., 2006). Up to 50% of patients with FTD report a family history 
of dementia, suggesting a strong genetic component associated with this disease 
(McKhann et al., 2001; Ghidoni et al., 2011). FTD is an umbrella term for a diverse group 
of disorders which are primarily caused by atrophy or shrinkage of the frontal and 
temporal lobes of the brain, and so, the clinical symptoms generally associated are 
behavior and personality changes, cognitive impairment and language disorders of 
expression and comprehension (McKhann et al., 2001; Goedert et al., 2012).  
 
1.2.4.1. Neuropathological Hallmarks of FTD 
As mentioned, the major distinguishing anatomical hallmarks of FTD is the selective 
atrophy of the frontal and/or temporal lobes due to neuronal loss, also accompanied by 
gliosis and spongiosis of the superficial layers. The atrophy is sometimes asymmetric and 
may involve subcortical brain regions, such as the basal ganglia or the hippocampus (Bird 
and Miller, 2010; Seelaar et al., 2011; Goedert et al., 2012). At the histopathological level, 
FTD may be characterized as FTLD-τ or FTLD-U if Tau-positive neuronal inclusions (Figure 
6A) or if ubiquitin-positive and Tau-negative neuronal inclusions are present, respectively. 
Figure 5: Lewy body inside a neuronal cell. Lewy body 
was stained for ubiquitin (arrow). From Chu et al. 
(2000). 
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For the latter cases, besides ubiquitin, other proteins may be found in these inclusions. 
Transactive response-DNA binding protein-43 (TDP-43) was identified as the major 
component of the inclusions in most cases of FTLD-U, which are now called FTLD-TDP 
(Figure 6B). Most of FTLD-U cases negative for TDP-43 were discovered to be positive for 
fused in sarcoma (FUS) protein, which made up the FTLD-FUS subtype. Additional rare 
forms remain to be discovered, because inclusions negative for TDP-43 and FUS, but 
positive for components of the ubiquitin-proteasome system (UPS), have been described 
and defined as FTLD-UPS. Around 40% of FTD patients show Tau positive inclusions, 50% 
show TDP-43 inclusions and less than 10% have FUS inclusions (reviewed in Goedert et al. 
(2012)). Nonetheless, despite the heterogeneity of the underlying neuropathology, 
clinical symptoms correlate better with specific patterns of brain atrophy in each FTD case 
(Goedert et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Histopathological hallmarks in FTLD patients. A – FTLD-τ brain. Numerous Tau-
immunoreactive inclusions are seen inside the neurons. From Cairns et al. (2007).               
B – FTLD-TDP brain. Abundant TDP-43 immunoreactive compact neuronal cytoplasmic 
inclusions and short dystrophic neuritis, often with neuronal intranuclear inclusions. From 
Goedert et al. (2012). 
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1.2.5. Huntington’s Disease 
HD is a neurodegenerative disorder that is transmitted within families from 
generation to generation, caused by mutated huntingtin gene (HTT). The mean age at 
onset is between 30 and 50 years, but it can range from 2 to 85 years, and is 
characterized by chorea, behavioral and psychiatric disturbances and dementia. Usually, 
memory is unaffected until late stages of the disease, but attention, judgment, 
awareness, and executive functions may be seriously impaired even in early stages. The 
progression of the disease leads to more dependency in daily life and ultimately to 
patients death. The most common cause of death is pneumonia, followed by suicide 
(Huntington, 1872; Bird and Miller, 2010). 
 
 
1.2.5.1. Neuropathological Hallmarks of HD 
Distinct topographic and cellular alterations, notably in the striatum and cerebral 
cortex, are characteristic of HD. Patients suffering from this disease have a total brain 
volume smaller, when compared to normal individuals, with a marked neuronal loss 
observed in the striatal area. Also, nuclear or cytoplasmic inclusions in neurons and glial 
cells are present, which can be detected long before the symptoms onset in otherwise 
apparently normal brains of asymptomatic gene carriers. These inclusions contain 
ubiquitin and the mutated huntingtin protein (Figure 7), and contribute to the disease 
neurodegenerative process (Gomez-Tortosa et al., 2001; Vonsattel, 2008; Zuccato et al., 
2010). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Neurons of a HD patient displaying intranuclear 
inclusions. Inclusions were stained for ubiquitin and huntingtin. 
From (Crichton et al., 2008). 
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1.2.6. Alcohol Related Dementia 
The influence of alcohol on health varies depending on the amount consumed, 
drinking duration, type of alcohol and frequency, environmental factors and family 
history. Frequent heavy drinking or binge drinking is associated with alcohol dependence, 
alcohol-related cognitive impairment and ARD, which may lead to severe social, 
economic, physical, and psychological burdens (Oscar-Berman and Marinkovic, 2003; 
Panza et al., 2009; Fichter et al., 2011). In people diagnosed with ARD, the cognitive 
deficit manifests as poor working memory, decreased verbal fluency, perseveration, 
impaired abstraction and decreased behavioral initiation (Saxton et al., 2000). 
 
1.2.6.1. Neuropathological Hallmarks of ARD 
Magnetic resonance imaging (MRI) scans of ARD patients show ventricular 
enlargement and diffuse brain atrophy affecting the prefrontal regions (Figure 8) 
(Pfefferbaum et al., 1997; Pfefferbaum et al., 1998). 
 
 
 
 
 
 
 
These brain alterations are due to neurotoxic effects caused by chronic alcohol 
abuse, leading to cognitive impairment (Verbaten, 2009). The cognitive deficits may be 
mediated directly through damage in brain structures or indirectly through malnutrition, 
metabolite toxicity, electrolyte imbalance, or accompanying physical illnesses including 
liver disease and infection (Neiman, 1998). The direct neurotoxic effect of alcohol is 
Figure 8: Brains of age-equivalent men with different 
histories of alcohol use. The image shows clear evidence of 
brain shrinkage in the alcoholic compared with the control 
subject. Adapted from Oscar-Berman and Marinkovic (2003). 
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mediated via its action on the N-Methyl-D-aspartate (NMDA) receptors of glutamatergic 
neurons. Acute alcohol intake exerts an inhibitory effect on NMDA receptors and, thus, 
induces receptor up-regulation. However, when alcohol intake ceases, the up-regulated 
receptors are no longer inhibited, still resulting in excessive stimulation of NMDA 
receptors and calcium influx, consequently leading to cytotoxic effects. Glutamatergic 
neurons are densely concentrated in the frontal lobes and subcortical areas such as the 
hippocampus, and these brain regions are particularly vulnerable to excitotoxic effects 
produced by alcohol intake (Verbaten, 2009). The neuropsychological deficits and brain 
damage caused by ARD may be partially reversed with continued abstinence (Shear et al., 
1994; Pfefferbaum et al., 1995). 
Since no specific genetic basis has been described for this disease, and once ARD is 
clinically different from AD and VaD (Oslin and Cary, 2003), it will not be addressed in the 
subsequent sections.  
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1.3. GENETIC BASIS OF DEMENTIA 
Many dementing disorders show an extensive family history, suggesting a 
substantial contribution of hereditary genetic factors to disease onset and progression. 
This section will focus on the main genetic factors associated with the most common 
forms of dementia. 
 
1.3.1. Alzheimer’s disease 
Familial cases of AD (age of onset <65 years) represent less than 5% of total cases 
and are caused by mutations in 3 different genes: APP, Presenilin 1 (PSEN1) and Presenilin 
2 (PSEN 2). Although AD-causing mutations occur in 3 different genes located in 3 
different chromosomes, they all share a common biochemical pathogenic pathway, 
converging on the Aβ peptide (Table 1). Unrevealing the molecular mechanisms 
underlying the disease pathogenesis will contribute not only to the understanding of the 
genetic cases, but also of the sporadic forms, since increased Aβ production and 
accumulation into SPs is a common feature in both cases. Age, environment, decreased 
reserve brain capacity and reduced mental and physical activity during life are among the 
factors associated with sporadic cases (Mortimer et al., 2003; Gatz et al., 2006). 
Nonetheless, genes that increase the susceptibility to develop the disease have also been 
linked with these cases. Apolipoprotein E gene (ApoE) is such an example, with several 
studies demonstrating a strong correlation between the presence of ApoE allele ε4 and 
AD development (Noguchi et al., 1993; Roses, 1996; Rocha et al., 1997; Josephs et al., 
2004; Kim et al., 2009). 
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1.3.2. Vascular Dementia 
Fewer studies have been done in order to examine the genetic associations of VaD 
(Jones et al., 2011), partly due to the heterogeneity of this disorder. The particular 
subtype of VaD, CADASIL, is a hereditary condition resulting from mutations in NOTCH3 
gene (Table 1) (Ungaro et al., 2009). In general, proposed genetic risk factors associated 
with an increased susceptibility to develop VaD include MTHFR gene 
(Methylenetetrahydrofolate reductase) and also the ApoE, like for AD (Jones et al., 2011). 
Nevertheless, a lack of association between the last gene and VaD development was also 
reported (Sulkava et al., 1996; Kim et al., 2008).  
 
1.3.3. Dementia with Lewy Bodies 
DLB occurs sporadically in most cases, but familial forms also exist, suggesting the 
importance of genetic determinants. Recent molecular genetic discoveries are now 
revealing that DLB is etiologically heterogeneous, and the known genetic determinants of 
DLB overlap substantially with those of PD (Bonifati, 2008). The main mendelian genes 
associated with DLB are for now SNCA (Zarranz et al., 2004) and LRRK2 (Ross et al., 2006) 
(Table 1), which are also genetic factors associated with PD. ApoE gene has also been 
proposed as a risk factor for DLB development (Harrington et al., 1994), but this finding is 
still controversial (Carrillo Garcia et al., 2008). 
 
1.3.4. Frontotemporal Dementia  
A strong genetic component is linked to FTD, as FTD patients report a family history 
of dementia in up to 50% of the cases. Nevertheless, the clinical and neuropathological 
variability of the syndrome suggests the existence of several distinct genetic factors 
underlying or modifying disease pathogenesis (Table 1) (Bertram and Tanzi, 2005). In fact, 
mutations in MAPT gene are associated with FTLD-τ, while mutations in progranulin 
(PGRN) gene are associated with FTLD-TDP (Kumar-Singh and Van Broeckhoven, 2007; 
Goedert et al., 2012). These are the main genes responsible for hereditary forms of FTD, 
however, mutations in VCP, FUS and CHMP2B genes can also lead to disease, but at a 
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much lower frequency. With respect to susceptibility genes, it has been shown that 
TMEM106B variants may increase the risk of FTD development, in particular the FTLD-U 
subtype (Van Deerlin et al., 2010). As for DLB and VaD, the role of ApoE as a risk factor for 
FTD is not consensual (Geschwind et al., 1998; Borroni et al., 2006), and additional studies 
should be carried out to establish the association. 
 
1.3.5. Huntington’s Disease 
HD is an autosomal dominant degenerative brain disorder. A DNA elongated CAG 
repeat on the short arm of chromosome 4p16.3 in the HTT gene is the basis of the 
pathological process (Table 1). The non mutated gene contains CAG repeats, coding for a 
polyglutamine stretch in the protein, in the range 6 to 26. HD is associated with 36 CAG 
repeats or more, that results in the formation of HTT with polyglutamine expansions. 
Definite clinical manifestation will occur if the number of repeats exceeds 40. The range 
36-39 leads to an incomplete penetrance of the disease or to a very late onset. The range 
between 27 and 35, the so-called intermediate alleles, is unstable, which means that 
these alleles are prone to changes during reproduction, thus increasing the propensity of 
the next generation to develop the disease (Trottier et al., 1994; Walker, 2007).  
Comparatively to other forms of dementia, HD is easier to diagnose using currently 
available genetics base diagnostics, thus it will not be further discussed in the work here 
presented. 
 
Table 1 exhibits the principal inherited genes linked to the dementing disorders 
discussed above. The main proposed mechanisms in the base of disease pathogenesis 
caused by the mutated genes were also included.  
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Table 1: Main mendelian genes associated with AD, FTD, VaD, DLB and HD. (Selkoe, 1998; Brunkan and Goate, 
2005; Zuccato et al., 2010; Duering et al., 2011; Lill and Bertram, 2011). 
 
  
Disease Gene Protein Mechanism of pathogenesis 
AD 
APP Amyloid precursor protein 
Increases Aβ1-42 production from 
APP processing 
PSEN1 Presenilin 1 
Promotes cleavage at γ-secretase 
site and increases Aβ1-42 
production and accumulation 
PSEN2 Presenilin 2 
Promotes cleavage at γ-secretase 
site and increases Aβ1-42 
production and accumulation 
VaD NOTCH3 
Neurogenic locus notch 
homolog protein 3 
Accumulation and deposition of 
the NOTCH3 (N3) extracellular 
domain in small blood vessels 
DLB 
SNCA α-synuclein 
Aggregation of α-synuclein; altered 
neurotransmitter release and 
vesicle turnover 
LRRK2 Leucine-rich repeat kinase 2 
Mishandling of a-synuclein, 
reduction of neurite outgrowth, 
alteration of endosomal trafficking 
FTD 
PGRN Progranulin 
Impaired neuronal survival; 
inflammation 
MAPT 
Microtubule-associated 
protein Tau 
Impaired microtubule assembly 
and axoplasmic transport 
CHMP2B 
Chromatin modifying protein 
2B 
Interference with endosome-
lysosome fusion 
VCP Valosin-containing protein 
Impaired proteasomal 
degradation, altered membrane 
sorting at endosomes/degradation 
in lysosomes, impaired 
endoplasmic reticulum induced 
stress response 
HD HTT Huntingtin 
Accumulation of NH2 terminal 
fragments of mutated HTT, 
impairment of signaling processes 
and homeostasis, proteasomal and 
mitochondrial dysfunction, 
impaired gene transcription, 
altered vesicular transport  
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1.4. APOE AS A GENETIC RISK FACTOR FOR DEMENTIA 
ApoE genotype has been proposed as a risk factor for various types of dementia. 
However, a strong correlation for this gene with disease development is better 
established for AD. In particular, it seems clear that APOE isoform 4 plays an important 
role in the pathogenesis of this disease, while controversial data have been reported for 
other dementias. 
 
1.4.1. APOE role 
Human APOE is a lipoprotein of 317 aminoacids that is expressed in many organs, 
with the highest expression in the liver, followed by the brain. APOE exists mainly as a 
component of lipoprotein complexes along with other apolipoproteins and proteins in 
plasma and cerebrospinal fluid (CSF). It is encoded by the ApoE gene (19q13.2), where 
alleles ε2, ε3 and ε4 give rise to the three major polymorphic forms of APOE: APOE2 
(Cys130, Cys176), APOE3 (Cys130, Arg176) and APOE4 (Arg130, Arg176). Aminoacid 
differences at these positions are crucial as they alter the charge and structural properties 
of the protein, which may ultimately influence the functional properties of the APOE 
isoforms, such as stability, folding characteristics, lipoprotein particle preferences and 
binding affinities to low density lipoprotein receptor (LDLR) and LDLR related protein 
(LRP) (Davignon et al., 1988).  
APOE is one of the key components in lipoprotein complexes that regulate lipid 
metabolism by directing their transport, delivery and distribution from one tissue or cell 
type to another (Mahley, 1988). In addition, this lipoprotein may be involved in many 
other physiological and pathological processes, including immunoregulation, nerve 
regeneration, activation of lipolytic enzymes, ligand for several cell receptors, neuronal 
homeostasis and tissue repair (Mahley and Rall, 2000). In the brain, APOE is mainly 
produced by astrocytes, but also by microglia and neurons (Kim et al., 2009), and plays an 
essential role in cholesterol and phospholipid transport to neuronal membrane 
regeneration and remyelination sites (Lane and Farlow, 2005).  
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1.4.2. ApoE and dementia  
Not only familial but also sporadic forms of dementia are likely to be substantially 
controlled by genetic factors, given that possible risk genes may be involved. ApoE has 
been one of the most studied risk factors, mainly associated with sporadic cases. A series 
of landmark studies identify a strong association between the presence of the isoform 
APOE4 and an increased risk for AD: the susceptibility to develop the disease is more 
strongly associated with APOE4 than with APOE3 and in turn more strongly with APOE3 
than with APOE2, the latter suggested to have a protective role in the disease (Corder et 
al., 1994; Panza et al., 2000). The presence of one ApoE ε4 copy increases the risk to 
develop AD by about three times and two copies by about 12 times (Saunders, 2000). 
Also, the ApoE ε4 allele modifies age of disease onset (Meyer et al., 1998; Xiong et al., 
2005), with each allele copy lowering the age of onset by almost 10 years, suggesting that 
APOE4 association with AD may be related to longer disease duration in these cases 
(Basun et al., 1995).  
Although the mechanism by which APOE isoforms affect the risk to develop AD is 
not entirely understood, relevant evidence have been demonstrated: 
(i) there is strong evidence that APOE isoforms differentially modulate Aβ 
metabolism; in-vitro and in-vivo studies show that APOE has an important 
role in determining whether and when Aβ converts from a monomeric, non-
toxic molecule into higher-molecular-weight forms such as oligomers and 
fibrils, certain forms of which probably mediate neurotoxic effects 
(Wisniewski et al., 1994; Castano et al., 1995); 
(ii) APOE isoforms differentially regulate Aβ clearance from the brain: increased 
Aβ accumulation has been demonstrated in carriers of  ε4 allele  (Polvikoski 
et al., 1995; Castellano et al., 2011; Bachmeier et al., 2012);  
(iii) Genotype also influences pathological changes in relation to the time course 
of disease onset by affecting the probability that Aβ begins to deposit, such 
that the timing of accumulation is shifted to an earlier age depending on 
APOE isoforms, in particular, APOE4 (Figure 9) (Jack et al., 2010) 
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(iv) Allele 4 of ApoE may be more vulnerable than other isoforms to aberrant 
degradation thereby limiting lipid mobilization for neuronal repair, 
neuroplasticity and cognitive reserve in the face of the neurodegenerative 
process (Finch and Sapolsky, 1999; Acharya et al., 2002); 
(v) Enhanced formation of C-terminal-truncated fragments characteristic of E4 
isoform stimulates Tau hyperphosphorylation and the formation of NFTs 
(Harris et al., 2003) 
(vi) Ischemic brain insults and hypertension-related white matter lesions, known 
contributors to the severity of dementia in AD, tend to be more pronounced 
in ε4-positive patients (de Leeuw et al., 2004)  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: ApoE as a genetic risk factor for AD. (A,B) Relative to a fixed age (here, 65 years), the 
hypothesized effect of ApoE ε4 is to shift β-amyloid plaque deposition and the neurodegenerative 
cascade both to an earlier age compared with ε4 non-carriers, lowering the age of disease onset. 
MRI – Magnetic resonance imaging. Adapted from Jack et al. (2010). 
Genetic profiling of ApoE in Dementia 
 
20 
Numerous studies have investigated putative associations of ApoE genotype with 
risk of progression of various other dementing disorders (Table 2), nevertheless the data 
reported has been controversial. While some studies reported that the frequency of allele 
ε4 of ApoE is increased in VaD, FTD and DLB (Noguchi et al., 1993; Harrington et al., 1994; 
Morris et al., 1996; Ingelson et al., 2001; Baum et al., 2006; Borroni et al., 2006; Davidson 
et al., 2006), other authors have reported that there are no evidence of association 
between the individual ApoE genotype and the development of the diseases mentioned 
above (Sulkava et al., 1996; Geschwind et al., 1998; Verpillat et al., 2002; Nielsen et al., 
2003; Carrillo Garcia et al., 2008; Kim et al., 2008). Hence, the relationship between 
APOE4 and VaD, FTD or DLB remains uncertain. Interestingly, contrary to what happens in 
AD, where allele ε2 is a protective factor, some studies have proposed that the expression 
of this allele can be a risk factor for FTD (Lehmann et al., 2000; Verpillat et al., 2002). 
 
Table 2: Association of ApoE genotype with occurrence and progression of neurological disorders. Reviewed in 
Verghese et al. (2011).  
 Disease occurrence  
(level of evidence) 
Disease progression  
(level of evidence) 
AD ε4>ε3>ε2 
 (sufficient evidence of direct relation)
1
 
Inadequate or insufficient evidence
2
 
VaD ε4>non-carriers 
 (suggestive evidence of association)
3
 
Inadequate or insufficient evidence
2
 
FTD Inadequate or insufficient evidence2 Inadequate or insufficient evidence2 
DLB ε4>non-carriers 
 (suggestive evidence of association)
3
 
Inadequate or insufficient evidence
2
 
Levels of evidence were adapted from the categories established and used by the US Institute of Medicine for association between a 
factor and a specific health outcome. 1Evidence fulfils guidelines for sufficient indication of an association, is supported by 
experimental data in humans and animals, and satisfies several of the guidelines used to assess causality (strength of association, 
dose–response relation, and consistency of association). 2Evidence is of insufficient quantity, quality, or consistency to permit a 
conclusion about the existence of an association between ApoE and the neurological disorder in humans. 3Evidence is suggestive of 
an association between ApoE and the neurological disorder in humans, but the body of evidence is restricted by the inability to 
exclude chance, bias, and confounding factors with confidence. 
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1.5. DIAGNOSIS OF DEMENTIA 
Many dementing disorders share a number of clinical, pathological and molecular 
characteristics that complicate diagnosis specificity, due to the high degree of overlap in 
the associated symptoms across diverse dementia types (Bertram and Tanzi, 2005; Reilly 
et al., 2010). Differential diagnosis of dementia is typically done by clinical evaluation, 
that includes cognitive and behavior assessment, neuroimaging exams and a weighted 
combination of genetic and protein biomarkers. Regarding protein analysis, a recent 
promising and accurate tool emerged in the neuroscience field based on the evaluation of 
a panel of CSF biomarkers, whose pattern allows for the distinction among 
neurodegenerative diseases. This novel CSF-based neurochemical diagnosis is currently 
used in Europe and is starting to be established in Portugal. It seems a promising tool that 
will assist clinical diagnosis and hopefully help in overcoming dementia misdiagnosis. 
 
1.5.1. Clinical Diagnosis 
Clinical diagnosis requires general physical and neurological examination, behavior 
and cognitive neurological assessment, including attention, concentration, language, 
memory and learning ability, as well as visuospatial and executive functions. To confirm 
cognitive impairment and to follow the progression of dementia, screening tools such as 
the mini-mental state examination (MMSE) are usually used. MMSE is an easily 
performed 30-point test of cognitive function that contains orientation, working memory 
(e.g., spell world backwards), episodic memory (orientation and recall), language 
comprehension, naming and copying tests. In most patients with MCI and some with 
clinically apparent AD, the MMSE may be normal and additional neuropsychological tests 
may be required, such as DemTect or the clock drawing test (Bird and Miller, 2010; 
Eschweiler et al., 2010). This clinical diagnosis is not 100% conclusive and needs additional 
exams for neuronal cognitive examination and evaluation. Once the cognitive deficits 
have been objectively demonstrated, further investigations requires brain imaging and 
laboratory testing (Kester and Scheltens, 2009). Although head computerized tomography 
(CT) enables judgments of brain atrophy patterns and of vascular changes, the MRI 
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affords higher resolution without exposing the patient to ionizing radiation. Furthermore, 
the techniques of single photon emission computerized tomography (SPECT) and positron 
emission tomography (PET) can also be used to study cerebral perfusion and to measure 
brain energy metabolism, or, more recently, to quantify Aβ burden inside the brain (by 
using a chemical, named Pittsburgh Compound-B) (Klunk et al., 2004; Rowe et al., 2007; 
Tartaglia et al., 2011). Relative to laboratory tests, analysis of blood biomarkers to assess 
thyroid, liver and renal functions, as well as complete blood count, electrolytes, vitamin 
B12 and APOE levels, as well as urine toxin screen, should be performed in order to discard 
other possible causes of dementia such as hypothyroidism, vitamin B12 deficiency, chronic 
infection, brain tumor and drug intoxication (Bird and Miller, 2010). However, the biggest 
disadvantage of the clinical diagnosis is that in some cases it confirms pathology but only 
in a late stage, where cognitive impairment is already evident.  
The main clinical symptoms and signs associated with the most frequent dementias 
are presented in Table 3. The overlap of the vast possible clinical symptoms among the 
various dementing disorders is clearly evident, which may turn difficult the interpretation 
of the disease stage and the accurate clinical diagnosis of the pathology. Moreover, the 
occurrence of mixed dementia (MD) cases further complicates the diagnosis. MD is a 
condition in which abnormalities characteristic of more than one type of dementia occur 
simultaneously in the brain. In the most common form of MD, the abnormal protein 
deposits associated with AD coexist with blood vessel problems linked to VaD. However, 
Alzheimer’s brain changes coexistent with LBs are also often observed, or even, in some 
cases, a person may have brain changes linked to AD, VaD and DLB. MD symptoms may 
vary, depending on the brain alterations involved and regions affected 
(http://www.alz.org; Zurad, 2001; Jellinger and Attems, 2007; Dubois et al., 2010). 
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Table 3: Neuropathological characteristics and symptoms of the most common dementias. (Ritchie and Lovestone, 
2002; Armstrong et al., 2005; Bird and Miller, 2010; Reilly et al., 2010; Tartaglia et al., 2011). 
 
 
1.5.2.  Neurochemical Diagnosis  
As mentioned before, sometimes it is complicated to differentiate among 
dementing syndromes due to the overlap of diverse signals and symptoms, which may in 
some cases contribute to misdiagnosis. Recently, a reliable approach to differentiate 
benign cognitive deficits from AD and other dementias has been established, based on 
patient´s CSF biochemical analysis (Lewczuk et al., 2009; Dubois et al., 2010; Zetterberg et 
al., 2010). In this neurochemical diagnosis, a set of biomarkers can be evaluated, 
including: 
Disease Early Symptoms Late Symptoms 
Neuropsychiatric 
Symptoms 
Pathological 
Characteristics 
Neuroimaging 
AD 
Memory 
impairment (verbal 
and visual), 
personality changes 
Memory and 
language 
problems worsen, 
difficulty 
performing 
activities of daily 
living, visuospatial 
problems, 
disorientation 
Mild depressive 
features, social 
withdrawal, denial 
of illness, 
delusions, 
agitation, apathy, 
hallucinations, 
euphoria 
Senile Plaques, 
Neurofibrillary 
Tangles 
Hippocampal and 
diffuse cortical 
atrophy, reduced 
glucose 
metabolism in the 
superior/posterior 
temporal and 
parietal regions 
VaD 
Mixture of deficits 
in executive  and 
spatial functions, 
memory 
impairment, mild 
confusion, 
personality changes 
Difficulties in 
judgment and 
orientation, 
dependence on 
others for daily 
activities 
Depression, 
delusions, 
disinhibition, 
apathy, 
hallucinations 
Ischemic lesions 
Large white-matter 
abnormalities, 
cortical and/or 
subcortical 
infarctions 
DLB 
Visual 
hallucinations, 
language 
disturbance, 
parkinsonian 
symptoms, 
memory can be 
affected 
Severe 
visuospatial 
symptoms, 
movement 
disorders 
Delusions related 
to personal 
identity, day-to-
day fluctuations, 
depression 
Lewy bodies 
Posterior parietal 
atrophy, 
hippocampus 
larger than in AD 
FTD 
Deficit in frontal 
executive or 
language functions, 
personality 
changes, increased 
apetite, compulsive 
or repetitive 
behavior 
Memory loss,  
problems 
maintaining 
normal 
interactions and 
following social 
conventions 
Depression, 
apathy, 
disinhibition, loss 
of empathy, 
anxiety 
Tau or ubiquitin 
inclusions 
Focal frontal 
and/or anterior 
temporal atrophy, 
hypometabolism in 
the frontal and 
anterior temporal 
regions 
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Aβ1-42 – Amyloid pathology assessment is relevant because of its robust association 
with AD, as this seems to be the earliest biochemical change during the course of the 
disease (Stomrud et al., 2007; Fagan et al., 2009). Low CSF levels indicate retention of Aβ1-
42 in the brain parenchyma (Strozyk et al., 2003; Grimmer et al., 2009); 
Phospho-Tau – Tangle pathology is the most specific finding suggesting an ongoing 
AD process in the brain (Hampel et al., 2010). Elevated P-Tau 181 levels in CSF correlates 
with MCI and with neocortical neurofibrillary pathology in AD (Buerger et al., 2002; 
Buerger et al., 2006). The reason why P-Tau 181 levels are normal in FTD patients is to 
date unknown (Bian et al., 2008); 
Total-Tau – Increased CSF levels of T-Tau traduce axonal degeneration: the more 
pronounced increase, the more intense degenerative process and the faster the disease 
progression (Hampel et al., 2010). The cortical axonal degeneration in AD makes elevated 
T-Tau an obligatory finding. Very high levels predict a rapid cognitive decline in AD (Blom 
et al., 2009) and short survival in DLB (Bostrom et al., 2009); 
Neurofilament light protein (NFL) – it is the best-established biomarker for sub-
cortical axonal degeneration/damage. This kind of degeneration is frequently seen in VaD 
(Rosengren et al., 1999; Wallin and Sjogren, 2001) and FTD (de Jong et al., 2007). Elevated 
NFL levels in CSF help in differentiating pure AD from other conditions; 
CSF/serum albumin ratio – this ratio is a direct measurement of blood-brain barrier 
(BBB) integrity. Typically, the CSF/serum albumin ratio is normal in patients with pure AD, 
while patients with vascular dementia generally present an elevated ratio (Blennow et al., 
1990; Wallin et al., 1999); 
Inflammation biomarkers – white blood cell count and Immunoglobulin G (IgG) or 
Immunoglobulin M (IgM) production, within central nervous system (CNS), are in general 
negative in AD, VaD, FTD and DLB (Blennow et al., 1990). When positive results are 
obtained it is an indication that other neuroinflammatory conditions may contribute to 
the cognitive symptoms observed and must be investigated.  
Table 4 summarizes the typical changes in relation to different diagnosis entities. 
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  Table 4: CSF-based neurochemical diagnosis of dementia. Adapted from Zetterberg et al. (2010). 
 
As evident, the evaluation of these CSF biomarkers allows differential diagnosis of 
dementia and is more precise as more biomarkers are considered. Of note, according to 
some authors, alterations in CSF levels of Aβ1-42, P-Tau 181 and T-Tau can identify AD with 
dementia and prodromal AD in patients with MCI with 75-95% sensitivity and specificity 
(Hansson et al., 2006; Mattsson et al., 2009; Shaw et al., 2009; Visser et al., 2009). Thus, 
the neurochemical diagnosis, in particular the evaluation of Aβ1-42 biomarker, allows for 
the earliest preclinical evidence for AD pathology (Figure 10). 
In comparison with other diagnostic tools, the sensitivity of the CSF analysis seems 
to be higher than, for example, neuroimaging techniques (Weih et al., 2009), which 
further validates it as a useful diagnostic tool. Nonetheless, the CSF biochemical data 
should be interpreted with great care and in combination with the entire clinical picture 
(Zetterberg et al., 2010). 
 
 
 
 
Diagnosis 
Amyloid 
pathology 
(Aβ1-42) 
Tangle 
pathology  
(P-Tau 181) 
Cortical 
axonal 
damage     
(T-Tau) 
Sub-cortical 
axonal 
damage 
(NFL) 
BBB 
dysfunction 
(CSF/serum 
albumin ratio) 
Inflammation 
(CSF cell counts, 
IgG or IgM 
production) 
AD Yes Yes Yes No No No 
VaD No No 
Yes 
(especially in 
relation to new 
brain infarcts) 
Yes Yes Yes 
DLB Yes No Yes 
(mild) 
No No No 
FTD No No Yes 
(mild) 
Yes No No 
Normal 
Aging 
No No No No No No 
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Neurofibrillary tangles
Senil Plaques
Neuronal Integrity
Max
Min
Non-AD Preclinical AD
(MCI) Mild AD Mod AD
Sev ADVery Mild AD(Non-demented)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.3. Genetic Diagnosis  
Progress in the genetics of dementing disorders and the availability of clinical tests 
for practicing physicians, increase the need for a better understanding of multifaceted 
issues associated with genetic testing. Even though the genetic basis of some dementia 
forms is complex and the fact that genetic testing is associated with ethical concerns 
(Hedera, 2001), a genetic approach may be of benefit in suspected familial forms of 
dementia, in particular when a highly penetrant gene mutation is inherited in an 
autossomal dominant pattern. In this situation, genetic testing may be an advantage since 
the identification of the specific mutations in affected family members will confirm the 
dementia diagnosis (Atkins and Panegyres, 2011). Examples of such situations include 
familial AD triggered by mutated APP, PSEN1 or PSEN2 genes, and FTD caused by 
mutations in MAPT and PGRN genes. However, as these usually represent a minor part of 
total cases of dementia, genetic testing is not a routinely used diagnostic tool for patient 
Figure 10: Biomarkers for early diagnosis of AD (proposed changes in biomarkers in relation to 
time course of pathological and clinical stages). The clinical stages of AD, marked by progressive 
dementia described as ‘very mild/mild cognitive impairment’ (MCI), ‘mild,’ ‘moderate,’ and 
‘severe,’ are associated with abundant SPs (red line), gradual accumulation of NFTs (blue line) and 
synaptic and neuronal loss in certain brain regions (green line). In the ‘preclinical’ stage of AD,   
Aβ1-42 peptide forms amyloid plaques in the brains of non-demented individuals for approximately 
10-15 years, and damages neuronal processes and synapses. AD biomarker research seeks to 
measure changes in the structure and function of the brain (e.g. atrophy, regional activity changes 
and hypometabolism, SPs and NFT formation, microgliosis, inflammation, oxidative stress) that 
might be useful for diagnosis and prognosis during this ‘preclinical’ phase of AD. Before 
irreversible neuronal loss occurs, a reduced concentration of CSF Aβ1-42 may provide the earliest 
definitive evidence of AD pathology in the brain. Adapted from Perrin et al. (2009).  
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evaluation and diagnosis. Further, genetic testing of affected patients should be 
accompanied by competent genetic counseling that focuses on probabilistic implications 
for at-risk first degree relatives.  
Even more controversy lies on the test of genetic susceptibility risk factors, 
associated with sporadic forms of dementia. Some authors consider that testing using 
susceptibility genes has only a limited diagnostic value because the potential 
improvement in diagnostic accuracy does not justify potentially negative consequences 
for first-degree relatives. Also, predictive testing of unaffected subjects using 
susceptibility genes should not be recommended because individual risk cannot be 
quantified and presently there are no therapeutic interventions for dementia in pre-
symptomatic patients (Hedera, 2001). On the other hand, some authors consider that this 
genetic testing may be important, in particular for genetic risk factors already described 
to be strongly associated with disease, such as ApoE for AD pathology. ApoE “advocates” 
claim that testing may be useful when used as a diagnostic adjunct (Roses, 1995; Xiong et 
al., 2005); if a patient exhibits symptoms of dementia, then the susceptibility testing may 
help determine what type of dementia the patient is suffering from (Roses, 1997).  
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2. AIMS OF THE THESIS 
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Dementia is among the most common and disabling diseases, which represents a major 
health problem in society, affecting nearly 36 million people worldwide. Disturbingly, numbers of 
dementia cases tend to rise even more due to increased average of life expectancy. Among the 
most common types of dementia are Alzheimer´s Disease (AD), Vascular Dementia (VaD), 
Dementia of Lewy Bodies (DLB) and Frontotemporal Dementia (FTD), whose diagnosis is not 
always accurate due to the wide possibility of symptoms overlap, in particular in the early stages 
of the disease. Understanding the environmental and genetic components that contribute to risks 
and outcomes of neurological diseases, could provide useful information with respect to the 
development and management of these devastating disorders.   
Apolipoprotein E is recognized as a powerful genetic risk factor, in particular for AD 
pathogenesis. Specifically, ApoE allele ε4 carriers have an increased risk of developing the disease, 
as this protein isoform has been described to play a role in Aβ oligomerization and its 
accumulation in the brain. Putative associations have also been proposed between this gene and 
other neurodegenerative disorders, although controversial data have been reported. Hence, the 
main goal of this thesis was to determine genotypic and allelic frequencies of ApoE gene in a pilot 
study group of neurological disease patients from the catchment area of the “Hospital de São 
Sebastião” in “Santa Maria da Feira”. This group was subdivided according to their neurochemical 
diagnosis of dementia (by analyzing a triplet of biomarkers, namely Aβ1-42, P-Tau 181 and T-Tau), 
which allowed for the characterization of the study group, in particular in distinguishing AD from 
other forms of dementia. The specific aims of this work were to: 
 
1. Isolate genomic DNA from blood samples of the study group patients; 
2. Quantify and evaluate purity of DNA extracted; 
3. Amplify the polymorphic regions of ApoE gene by Polymerase Chain Reaction (PCR) and 
determine the patients’ genotype through enzymatic restriction analysis; 
 
4. Determine the ApoE genotypic and allelic frequencies in the pilot study group. 
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3.1. STUDY GROUP 
Our pilot study group included a population of 32 individuals with neurological 
disease from the catchment area of the “Hospital de São Sebastião” in “Santa Maria da Feira”, 
herein referred to as “the catchment area”, whose age and gender variables are shown in 
Table 5. 
 
Table 5: Characteristics of age and gender from pilot study group. 
Variable  
Age (years) 
Mean (±SD)  
Min-Max 
 
 
68 (±10) 
46-85 
Gender 
Male n (%) 
Female n (%) 
 
14 (44%) 
18 (56%) 
 
Sample collection 
Blood was collected according to standard procedures in an EDTA tube, to prevent 
coagulation. Once arrived at the laboratory, samples were immediately aliquoted and 
frozen at -80°C. CSF samples were collected and stored according to pre-established 
procedures (“The Alzheimer’s Association Quality Control program for cerebrospinal fluid 
biomarkers”). 
 
3.2. CSF-BASED NEUROCHEMICAL ASSAYS 
Biochemical CSF analysis using an ELISA based approach for the evaluation of the 
biomarker triplet (Aβ1-42, P-Tau 181 and T-Tau), was carried out accordingly to the 
manufacturer’s instructions (Innogenetics, ELISA Kits). This analyses had been previously 
performed by colleagues from the Neuroscience Group, Center for Cell Biology. Results 
are here used to assist in the interpretation of the results. 
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Sample
LYSE BIND WASH 
(2x)
ELUTE Pure genomic 
DNA
3.3. APOE GENOTYPING 
ApoE genotyping was performed as described by Zuo et al., (2006), with minor 
modifications. Briefly, the genotyping procedure includes the Polymerase Chain Reaction 
(PCR) to amplify the polymorphic regions of ApoE gene, containing the coding portion for 
amino acid positions 130 and 176, from genomic DNA (gDNA) of each patient. Following 
amplification, PCR products were submitted to enzymatic restriction (ER) with HhaI. Each 
ApoE allele yields distinct fragment sizes, whose pattern was analyzed in an agarose gel 
electrophoresis system. 
 
3.3.1. Genomic DNA extraction   
 Genomic DNA (gDNA) was extracted from blood samples using the QIAamp DNA 
Blood Mini Kit (QIAGEN). In this procedure, DNA is adsorbed onto the silica membrane, 
under specific salt and pH conditions, and then eluted (Figure 11).  
 
 
 
 
 
 
 
 
Samples were equilibrated at room temperature and 200 μL of total blood used for 
gDNA extraction. Blood was added to 20 μL of protease and after that to 4 μL of RNase A 
100 mg/mL, for protein and RNA digestion (as the last can inhibit some downstream 
enzymatic reactions). Subsequently, 200 μL of lysis buffer were added and tubes mixed by 
pulse-vortexing for 45sec, to ensure that sample and buffer are mixed thoroughly and 
yield a homogeneous solution, for an efficient lysis. Additionally, tubes were incubated 
during 15min at 56°C. After a brief centrifugation step, 200 μL of ethanol (96-100%) were 
added, further mixed in the vortex for 15sec and briefly centrifuged again. This mixture 
Figure 11: General scheme for genomic DNA extraction. 
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was carefully applied on the spin column and centrifuged at 8000 rpm during 1min. DNA 
bound to the membrane was washed in two centrifugation steps: first at 8000 rpm for 
1min and second at 14000 rpm during 3 min, with 500 μL of two different wash buffers. 
Finally, 100 μL of elution buffer were applied to the columns. In order to enhance DNA 
recovery, this was done two times (50 μL + 50 μL). After each time, columns were 
incubated at room temperature during 5 min, followed by centrifugation at 8000 rpm for 
1min.  
To verify successful DNA extraction, 10 μL of each sample were analyzed by agarose 
gel electrophoresis.  
 
3.3.1.1. Agarose Gel Electrophoresis  
Agarose gel electrophoresis is a technique used for separation of DNA fragments. As 
DNA is a negatively charged molecule, it migrates from cathode to anode through the 
porous matrix of agarose, by an electric field, separating according to fragment size, as 
shorter molecules move faster and migrate further. The percentage of the gel depends on 
the DNA band size that we intend to analyze. 
To visualize gDNA extracted, 1% agarose gels were prepared in 1x TAE Buffer. The 
solution, heated until the agarose melted, was allowed to cool down to 60°C, and 
ethidium bromide (EtBr) was added to a final concentration of 0.05 mg/mL. The mixture 
was poured into the gel tray and left to set for 30-40min. For the gel run, the horizontal 
electrophoresis tank was filled with 1x TAE buffer. DNA samples were prepared and 
loading buffer (LB) added in the ratio 1:6, to increase sample density. Also, the presence 
of bromophenol blue in LB, add color to the sample facilitating loading and allowing track 
of electrophoresis. DNA ladder 1 kb plus (Invitrogen) was used. Gels were run at 90 V for 
40min and visualized under UV light in an AlphaImager HP System (Fisher Scientific).  
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3.3.1.2. DNA concentration and purity with Nanodrop  
In order to evaluate concentration and purity of gDNA extracted, 2 μL of each 
sample were analyzed, in duplicate, using the NanoDrop Spectrophotometer ND-1000 
(Thermo Scientific). Purity is given by the Abs260/Abs280 ratio and concentration is 
expressed in μg/μL. 
 
3.3.2. Amplification of ApoE gene by PCR 
PCR is a scientific tool to replicate DNA from a template, generating innumerous 
copies of a specific sequence with respect to the primers used. This technique was used 
to amplify a specific portion of ApoE gene (303 bp) from gDNA of each patient, using 
KlenTaq LA DNA Polymerase® (Sigma Aldrich) and primers FW - 
CGGGCACGGCTGTCCAAGGAG and Rev - CACGCGGCCCTGTTCCACCAG, which align with 
ApoE gene (NG_007084.2) as follows: 
 
 
 
Each PCR reaction was performed in a DNase free microtube using a mixture of 
components added according to the order in the following table.  
Figure 12: Primers alignment with ApoE gene sequence. 
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                                                  Table 6: PCR amplification mixture components. 
COMPONENTS VOLUME/REACTION 
(μL) 
DNA template (4ng/μL) 5,0 
Primer FW 10μM 1,0 
Primer Rev 10μM 1,0 
Betaine 5M 4,0 
dNTPs 10mM 0,4 
10x PCR Buffer 2,0 
Ultra-pure H2O 6,4 
KlenTaq LA DNA 
Polymerase Mix (5U/μL) 
0,2 
Total 20,0 
 
The thermocycler used was My CyclerTM (Bio-Rad). Cycle conditions for the 
denaturing, annealing and polymerization steps are indicated in Table 7. 
                                    Table 7: PCR conditions for ApoE polymorphic regions amplification. 
Nº OF CYCLES TEMPERATURE TIME  
1 95°C 5 min Initial denaturation 
35 
95°C 30 sec Denaturation 
64°C 30 sec Annealing 
68°C 30 sec 
Polymerization 
(extension) 
1 68°C 5 min Final extension 
- 4°C ∞  
 
In order to test if the expected DNA band size of 303 bp was amplified, 3 μL of each 
PCR product were analyzed in 2% agarose gel electrophoresis in 1xTAE buffer (see section 
3.3.1.1). Instead of EtBr, gels were stained with GreenSafe (nzytech), using 4 μL for 100 
mL of agarose solution. Samples were loaded with glycerol (1:6) as an alternative to LB, 
given that the latter can interfere with the visualization of 303 bp band. The ladder used 
was 1 kb plus (Invitrogen). Gels were run at 90 V for 45min and visualized in AlphaImager 
HP System (Fisher Scientific).  
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ApoE gene
Amplified product
PCR
ER HhaI
Constant cleavage sites
Variant cleavage sites
303bp
303
33     49                                             140    158                                   241  248   259 272       
68                                                 206                                                  
0
1    60                                       821  886                                                     1979   2171       2752                                         3612  bp
2837 bp 2139 bp
Exon 1 Exon 2 Exon 3 Exon 4
33    49                                            140    158                                   241  248   259   272       
Allele ℇ2 91bp 83bp
33    49                                            140   158                 206 241  248   259    272       
Allele ℇ3
91bp 48bp 35bp
33    49          68 140   158                  206  241  248   259    272
Allele ℇ4 48bp 35bp72bp
3.3.3. Digestion with restriction enzyme HhaI 
Restriction enzymes are a group of endonucleases which recognize specific 
sequences of DNA. They cleave double-stranded DNA (dsDNA) at specific sites within or 
adjacent to their recognition sequences, which differ for each restriction enzyme, 
producing differences in the length and sequence of the fragments resultant from an ER. 
For ApoE genotyping, HhaI (New England Biolabs®) was used to cut the 303 bp PCR 
products, within which there are eight constant and two variant HhaI cleavage sites - 
5’…GCG|C…3’. According to patients’ genotype, different patterns of fragment sizes can 
be produced (Figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: HhaI cleavage sites within ApoE amplicon. PCR fragments submitted to ER are cleaved in different 
fragment sizes, according to genotype:  ε2 allele loses variant cleavage sites resulting in 91bp+83bp+others (≤33bp) 
fragments; ε3 allele only has the variant cleavage site at position 206, resulting in 91bp+48bp+35bp+others (≤33bp) 
fragments; ε4 allele possess the two variant cleavage sites within its sequence, resulting in 
72bp+48bp+35bp+19bp+others (≤33bp) fragments. 
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ER was performed as listed below (Table 8) and reactions were incubated at 37°C 
for 17h. 
                                 Table 8: ER mixture components. 
COMPONENTS 
VOLUME PER REACTION 
(μL) 
Ultra-pure H2O 9,4 
PCR product 17,0 
10x NEBuffer4 3,0 
100x BSA 0,3 
HhaI 20U/μL 0,3 
Total 30,0 
 
 
3.3.4. Genotyping analysis 
ER fragments were analyzed by agarose gel electrophoresis (see section 3.3.1.1), in 
4% agarose gels with 1xTBE buffer, stained with GreenSafe (nzytech) (4μL for 100 mL of 
agarose solution). Glycerol was added to the samples in the ratio 1:6. Two different DNA 
markers were used: 10 bp DNA ladder (Invitrogen) and 1 kb plus (Invitrogen). Gels were 
run at 100 V, during 1h30min, and then visualized in AlphaImager HP System (Fisher 
Scientific).  
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4. RESULTS 
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4.1. EXTRACTION AND QUANTIFICATION OF GENOMIC DNA 
The main goal of this work was to evaluate the frequency of ApoE alleles and 
genotypes in a pilot study group of neurological disease patients from the catchment 
area. In order to accomplish this, the first step included gDNA extraction from patients 
(blood as source), using QIAamp DNA Blood Mini Kit (section 3.2.1). 
Following DNA extraction, 10 μL of each sample were analyzed by agarose gel 
electrophoresis and gDNA bands visualized under UV light (Figure 14).  
 
 
 
Figure 14: Genomic DNA extracted from blood samples of the study group. QIAamp DNA blood mini kit was used for 
extraction procedures and DNA samples were analyzed on 1% agarose gel. A band of ≈23kb was obtained in all cases. 
M – 1 Kb plus DNA Marker. 
Genetic profiling of ApoE in Dementia 
 
40 
y = -0,2887x + 5,0526
R² = 0,9946
3
4
5
1,0 2,0 3,0 4,0 5,0
Lo
g 1
0
[b
p
]
Traveled distance (cm)
The length of gDNA bands obtained was calculated by comparing the migration 
distance of the bands obtained with the reference bands of the DNA ladder used (1 kb 
plus). For that, a standard curve was defined based on the linear relationship between the 
traveled distance and the base 10 logarithm of fragments’ size (bp). Using the equation 
obtained from the reference points (Table 9 and Figure 15), where y represents Log10 [bp] 
and x represents the distance traveled, the size of the gDNA bands obtained could be 
extrapolated based on its migration distance. All gDNA bands run approximately 2,4 cm, 
corresponding to Log10[bp] ≈ 4,36 in the standard curve. Calculating the inverse function 
of this value, a size of about 23 kb was obtained. Considering the kit information, DNA 
extracted should be predominantly between 20-30 kb in length; therefore, the length of 
the gDNA extracted was as expected, for each patient DNA analyzed.  
 
Table 9: Measures of migration distances from DNA ladder 
fragments and logarithm of fragment sizes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MIGRATION 
DISTANCE  
(CM) 
DNA LADDER 
FRAGMENTS SIZE 
(BP) 
LOG10 [BP] 
3,4 12000 4,08 
3,6 10000 4,00 
3,8 9000 3,95 
4,0 8000 3,90 
4,2 7000 3,85 
4,4 6000 3,79 
Figure 15: Standard curve obtained for traveled distances of DNA marker 
fragments relatively to the logarithm of their sizes. In the resultant equation, y 
represents the Log10[bp], while x represents migration distance. 
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In order to evaluate the yield, concentration and purity of the DNA (Table 10), all 
samples were analyzed by spectrophotometry. The ratio of absorbance at 260nm and 
280nm is used to assess DNA purity. A value of ≈ 1,80 is considered as ‘pure’ DNA, while 
values higher than 1,80 mean contamination with RNA and values appreciably lower may 
indicate the presence of proteins, phenol or other contaminants that strongly absorb at 
or near 280 nm. The mean Abs260/Abs280 ratio was 1,77, indicating that, in general, 
gDNA extracted from blood samples of the study group have a good index of purity, being 
considered as pure.  
Table 10: NanoDrop measures for gDNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Sample Abs260/Abs280* 
[DNA]*  
(ng/µL) 
Total DNA extracted* 
(μg) 
01 1,85 24,2 2,4 
02 1,86 26,6 2,7 
03 1,80 31,2 3,1 
04 1,87 35,5 3,6 
05 1,77 46,9 4,7 
06 1,73 42,0 4,2 
07 1,78 38,5 3,8 
08 1,74 49,1 4,9 
09 1,74 23,0 2,3 
10 1,81 57,1 5,7 
11 1,77 40,3 4,0 
12 1,66 31,9 3,2 
13 1,65 25,1 2,5 
14 1,64 26,5 2,7 
15 1,77 53,2 5,3 
16 1,86 80,6 8,1 
17 1,84 41,3 4,1 
18 1,75 31,9 3,2 
19 1,79 30,8 3,1 
20 1,80 44,9 4,5 
21 1,77 32,0 3,2 
22 1,81 44,3 4,4 
23 1,74 32,2 3,2 
24 1,75 36,1 3,6 
25 1,77 34,6 3,5 
26 1,77 36,9 3,7 
27 1,81 49,1 4,9 
28 1,77 42,5 4,2 
29 1,76 33,6 3,4 
30 1,77 34,1 3,4 
31 1,79 41,0 4,1 
32 1,82 64,9 6,5 
* All values are mean of duplicate measurements 
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Total gDNA extracted was on average 3,9 μg. Accordingly to the manufacturer’s 
instructions the expected yield ranges from 3-12μg. In general, the results obtained for 
the study group are within the expected values, except for samples 01, 02, 09, 13 and 14 
that had lower total DNA yields. This can be due to a decreased number of white blood 
cells in patients’ blood samples, as this factor can vary greatly between different 
individuals according to age, sex, immune status and many other factors, thus influencing 
DNA yield. 
 
 
4.2. ORGANIZATION OF THE STUDY GROUP ACCORDING TO THE NEUROCHEMICAL 
DIAGNOSIS 
Before genotyping procedures, the pilot study group was organized according to the 
results obtained for the neurochemical analysis of patients’ CSF, which were previously 
realized in our laboratory. In brief, these clinically validated ELISA-based assays evaluate 
levels of Aβ1-42, T-Tau and P-Tau 181 levels in each patients´ CSF. This triplet of biomarkers 
was described to be useful in particular to distinguish AD from other forms of dementia 
(Zetterberg et al., 2010). According to the neurochemical diagnosis, the total neurological 
disease group (TD group) was subdivided in 3 main subgroups (Table 11): the AD positive 
group (AD group), that included patients with altered levels of the 3 biomarkers 
evaluated; the Aβ positive group (Aβ+ group) patients with only Aβ1-42 levels altered; and 
the other neurological disease group (OD group), composed of patients with no alteration 
in the levels of the triplet of biomarkers analyzed. According to this diagnosis, in our study 
group we had 8 AD individuals, 10 Aβ+ individuals and 14 individuals with OD.  
Subsequent analysis had in consideration these main groups. 
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Table 11: CSF-based neurochemical diagnosis of the pilot study group
1
.  
Sample Sex Age 
Amyloid 
Pathology 
(Aβ1-42) 
Tangle 
Pathology 
(P-Tau 181) 
Cortical 
Axonal 
Damage 
2
 
(T-Tau) 
Neurochemical 
diagnosis 
12 M 68 Yes Yes Yes 
AD + 
14 F 72 Yes Yes Yes 
06 F 78 Yes Yes Yes 
01 M 57 Yes Yes Yes 
02 M 85 Yes Yes Yes 
23 F 84 Yes Yes Yes 
29 F 76 Yes Yes Yes 
28 M 56 Yes Yes Yes 
30 M 58 Yes No No 
Aβ + 
07 F 85 Yes No No 
24 M 66 Yes No No 
31 F 78 Yes No No 
09 F 79 Yes No No 
16 F 79 Yes No No 
21 F 81 Yes No No 
17 M 68 Yes No No 
05 F 57 Yes No No 
04 M 46 Yes No No 
15 M 69 No No No 
OD 
03 M 60 No No No 
08 F 64 No No No 
10 M 59 No No No 
18 F 72 No No No 
25 F 64 No No No 
27 M 68 No No No 
22 M 69 No No No 
20 F 60 No No No 
11 M 64 No No No 
13 F 56 No No No 
26 F 77 No No No 
32 F 56 No No No 
19 F 60 No No No 
1
Evaluation of Aβ1-42, P-Tau 181 and T-Tau levels in patients CSF, to check for amyloid pathology, tangle pathology and 
cortical axonal damage, respectively. Patients were considered positive or negative comparatively to reference values for 
control individuals defined in the kit.  
2
Intermediate (mild) stages of cortical axonal damage were not considered here.  
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Figure 16: Patients range of ages in each group. Dashed lines represent patients mean ages. 
Visible differences between the established groups were observed, with AD group having the 
higher mean age value, while OD group comprises younger patients. 
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The mean age of patients was different between each of the established groups: for 
the AD group, the mean age was 72 years; for the Aβ+ group was 70 years; and for the OD 
group it was 64 years (Figure 16). The mean age observed for the AD group is consistent 
with a higher incidence of the late-onset sporadic forms. However, patients further from 
the mean could represent early-onset AD and should perhaps be subject to a follow-up 
study, i.e. subject number 1 and 28. 
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4.3. APOE POLYMORPHIC REGIONS AMPLIFICATION BY PCR 
In order to perform ApoE genotyping, the ApoE polymorphic regions were amplified 
by PCR. Results were visualized in 2% agarose gels and the expected fragment of 303 bp 
obtained in all cases (Figure 17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 17: ApoE polymorphic regions amplified by PCR. The product was a 303 bp 
band and was visualized in 2% agarose gel. A. Results of PCR amplicon for AD group. 
B: Results of amplicon for Aβ+ group. C. Results of PCR amplicon for OD group.          
M – 1 Kb plus DNA marker; C - – Negative control. 
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4.4. CORRELATING APOE GENOTYPING WITH DEMENTIA  
4.4.1. ApoE genotyping in the study group 
The product obtained by PCR was submitted to ER with HhaI to determine ApoE 
genotyping in the study group from the catchment area. Bands obtained were dependent 
on the genotype of each individual, and resulted from variant cleavage sites of the 
enzyme, as explained in section 3.3.3. In all cases, other small fragments were also 
produced, resulting from constant cleavage sites of HhaI within PCR fragment. Results 
obtained from the ER were analyzed in 4% agarose gel electrophoresis (Figure 18).  
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Analyzing the results from ER, we can conclude that the TD group included 1 
individual with genotype ε2ε3, 23 individuals with genotype ε3ε3, 6 individuals with 
genotype ε3ε4 and 2 individuals with genotype ε4ε4 (Table 12). Our study group 
comprised 8 individuals carriers of at least one copy of allele ε4 in their ApoE genotype, 
being that these patients mostly belong to the AD and the Aβ+ groups.  
 
 
 
 
 
 
Figure 18: Electrophoretic analysis of ApoE genotypes in the neurological disease study group. PCR 
product submitted to ER was cleaved in different fragment sizes, according to genotype:  ε2 allele – 
91bp+83bp+others; ε3 allele –  91bp+48bp+35bp+others; ε4 allele –  72bp+48bp+35bp+19bp+others. 
Fragments were visualized in 4% agarose gel A. Genotypes of patients from AD group. B. Genotype of 
patients from Aβ+ group. C. Genotype from patients of OD group. M1 – 1 Kb plus DNA Marker; M2 – 
10 bp DNA Marker; C - – Negative control.  
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Table 12: Total number of individuals with each genotype in the different groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.4.2. Determination of the ApoE genotypic and allelic frequencies in the 
study group 
According to the results obtained from genotyping procedures, the number of 
individuals with the ApoE genotypes and alleles were identified. 
The most frequent genotype in all groups was ε3ε3 (with a total of 23 individuals in 
the TD group), nonetheless, with a higher frequency in the OD group (85,8%), when 
compared with AD and Aβ+ groups (Table 12 and Figure 19). In the TD group, 8 out of 32 
patients were carriers of at least one allele ε4. The ε4ε4 genotype was only present in the 
AD and Aβ+ groups, corresponding to 12,5% and 10,0% of the patients. Similarly, ε3ε4 
genotype was most frequent in the same groups, 25,0% and 30,0% respectively, versus 
7,1% for OD group. The genotype ε2ε3 was only obtained in the OD group, corresponding 
to a frequency of 7,1%. Of note, in the total neurological disease group, no case was 
found to have genotypes ε2ε4 or ε2ε2, suggesting that allele ε2 is probably rare in the 
population. Considering all the individuals, the order of genotypes frequencies were:  
ε3ε3 > ε3ε4 > ε4ε4 > ε2ε3.  
 
 
 
 
 
 
Genotype 
Nº of individuals 
AD  Aβ + OD TD 
ε2ε2 0 0  0 0 
ε2ε3 0  0 1  1  
ε3ε3 5  6 12 23 
ε3ε4 2  3  1  6 
ε4ε4 1 1  0 2 
ε4ε2 0  0 0 0 
Total nº of 
individuals 8  10  14  32  
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60,0%
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62,5%
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N=8
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3,1%
71,9%
18,8%
6,2%
Total genotype frequency
ε2ε3 ε3ε3 ε3ε4 ε4ε4
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For the allelic frequencies (Table 13 and Figure 20), in agreement with the genotype 
frequencies obtained for the TD group, the most frequent allele was ε3 (53 alleles 
corresponding to 82,8%), followed by ε4 (15,6%) and by ε2 (1,6%).  
 
Table 13: Total number of each allele in the different groups. 
 
 
 
 
 
 
 
 
 
 
 
Allele 
Nº of alleles 
AD  Aβ + OD TD 
ε2 0 0 1 1  
ε3 12 15  26  53  
ε4 4 5 1 10 
Total nº of 
alleles 16 20  28  64  
Figure 19: Genotype frequencies in different groups. Genotype frequencies were calculated 
as a % of the total genotypes in each group. 
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Allele ε2 was only found in the OD group, with a frequency of 3,6%, the same as for 
allele ε4 in this group, while ε3 allele was present in 92,8% of the cases. Interestingly, 
allele frequencies in AD and Aβ+ groups were exactly the same for alleles ε3 and ε4, 
namely a frequency of 75,0% and 25,0%, respectively (Figure 20). 
 
 
 
 
 
 
 
Figure 20: Allelic frequencies in different groups. Each allele frequency was calculated     
as a % of the total number of alleles in each group. 
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5. DISCUSSION & CONCLUSIONS 
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The number of patients suffering from dementia has increased significantly due to 
extended life spans, resulting in a major health and socio-economic problem worldwide. 
Considering the limited effectiveness of possible interventions and diagnostic tools for 
the dementia cases available nowadays, studies have been focusing on understanding the 
molecular events and factors that may underlie the disease, and contribute to the 
development of early diagnostic tools and effective disease-modifying therapeutic 
approaches (Tanaka et al., 2008; Tanimukai et al., 2009). Also, understanding the 
interaction between environmental and genetic factors that modulate risks and outcomes 
of neurological disease can provide useful information about management of these 
devastating disorders (Verghese et al., 2011). 
Among the genetic aspects, the ApoE gene is recognized as the most powerful risk 
factor for dementia. It is believed that clinical findings related to ApoE should be taken 
into consideration, in order to reconcile gene and environmental interactions in the 
pathogenesis of dementia. The various proposed roles of APOE in CNS lipid homeostasis, 
synaptic activity, response to cellular injury and neuroinflammation, leads to many 
possible associations between this apolipoprotein and several diseases. However, so far, 
evidence for a strong association between ApoE genotype, specifically for allele ε4, 
remain the most compelling for AD. For the latter pathology, APOE  is believed to be 
linked to the risk of disease development through isoform dependent modulation of Aβ 
metabolism and accumulation (Wisniewski et al., 1994; Castano et al., 1995; Castellano et 
al., 2011; Bachmeier et al., 2012), as well as the decreased efficiency of APOE4 relative to 
other variants in recycling membrane lipids and neuronal repair (Poirier, 1994; Acharya et 
al., 2002). Further, ε4 allele has been associated to a lower age of AD onset in patients 
who are carriers (Xiong et al., 2005; Jack et al., 2010). However, the association between 
ε4 allele and other types of dementia, such as VaD, DLB and FTD, needs additional 
research to confirm whether ApoE is a relevant risk factor, or not, for those pathologies. 
In this perspective, the work here presented aimed to investigate the ApoE profile 
in a pilot study group of 32 patients suffering from neurological diseases. An important 
aspect of our work is that the pilot study group from the catchment area was divided 
according to the neurochemical diagnosis, which consisted in the evaluation of a triplet of 
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biomarkers (Aβ1-42, T-Tau and P-Tau 181) in patients’ CSF. This approach is a useful tool 
that helps in the characterization of the study group and, in particular, to distinguish AD 
from other types of dementia. Biomarker alterations occurring in the CSF are related with 
pathological processes occurring in the brain, even in the early stages of the disease 
(Zetterberg et al., 2010). According to the results obtained in neurochemical analyses, 
patients were organized into 3 main subgroups: AD group (patients with altered Aβ1-42, T-
Tau and P-Tau 181 levels), Aβ+ group (patients with only altered Aβ1-42 levels) and OD 
group (patients with none of the three biomarkers altered). An interesting aspect 
regarding the established groups is the difference between the mean ages of patients 
from each group: for AD group, average age was 72 years; for Aβ+ group it was 70 years; 
and for OD group it was 64 years. A lower mean age in Aβ+ group comparatively to AD 
group, is consistent with the idea that Aβ deposition may provide the earliest biochemical 
change during the course of AD, whereas synaptic loss and neuronal damage, as well as 
tangle pathology development, are only detected in a more advanced phase of the 
disease. Relative to the lower mean age in the OD group, we may speculate that these 
patients have predominantly dementia of early onset types, other than AD or DLB, 
probably associated to a stronger genetic component, such as FTD, or to lifestyle 
behaviors, such as alcohol or drug consumption related dementia (Figure 1). However, 
this would have to be further investigated. 
For all patients, gDNA was successfully extracted from blood samples, with a yield 
and purity level in agreement with the expected values for the kit used. In order to 
amplify ApoE polymorphic regions, PCR reactions were carried out and followed by ER 
analyses. Genotype and allelic frequencies of ApoE gene were determined in the groups 
subdivided according to the neurochemical diagnosis. Considering the TD group, the 
genotype frequencies were as followed: ε3ε3 > ε3ε4 > ε4ε4 > ε2ε3, with 71,9%, 18,8%, 
6,2% and 3,1%, respectively. However, for the 3 dementia subgroups established, the 
distribution of ApoE genotypic frequencies were significantly different (Table 12), with 
ε3ε4 and ε4ε4 genotypes being mainly detected in AD and Aβ+ groups, while ε2ε3 was 
only detected in OD group. Consistently, ApoE ε3ε3 was the most frequent genotype, 
independent of the group.  
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Regarding the ApoE allelic frequencies and comparing our data with Portuguese 
studies, we concluded that our data is consistent with prior observations (Table 14).  
Table 14: ApoE allelic frequencies obtained in previous Portuguese studies vs the study here 
presented.  
 Allele Frequencies  
ε2 ε3 ε4 
AD 3,4% 73,6% 23,6% 
(Fernandes et 
al., 1999) Controls 4,3% 90,0% 5,7% 
AD 0,0% 64,0% 36,0% 
(Rocha et al., 
1997) 
Controls-pw 2,2% 89,0% 8,8% 
Controls 4,3% 87,0% 8,7% 
AD  0,0% 75,0% 25,0% 
This study Aβ+ 0,0% 75,0% 25,0% 
OD 3,6% 92,8% 3,6% 
AD – Alzheimer’s Disease group; Controls – Control individuals group; Control-pw – Control-pairwise 
individuals group; Aβ+ – Aβ+ group; OD – Other neurological disease group. 
 
In particular, in our pilot study group, we could observe that ApoE allele ε3 was the 
most common in all groups. However, despite the elevated frequency of this allele in AD 
and in Aβ+ groups (75,0%), this value is even higher in OD group (92,8%). This is 
consistent with results obtained in previous studies where ApoE ε3 allele, independently 
of the presence or absence of disease, was the most frequent in the general population 
(Rocha et al., 1997; Fernandes et al., 1999), strongly represented by ε3ε3 genotype.  
ApoE allele ε2 was only found in OD group, with a frequency of 3.6%, being this 
allele the least represented in TD group. Moreover, the frequency of ε2ε4 and ε2ε2 
genotypes in the study group was 0,0%. These data are in agreement with the literature, 
that points to a very low prevalence of this allele in control individuals, but even more 
decreased in AD patients (Rocha et al., 1997; Fernandes et al., 1999). Further, the fact 
that no allele ε2 was found neither in AD nor in Aβ+ groups strengths the link previously 
proposed between the inheritance of ApoE ε2 and the low risk of developing the disease. 
This allele was reported to have a role as a protective element in sporadic AD (Corder et 
al., 1994; Panza et al., 2000).  
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Also, in the studies considered (Table 14), ApoE allele ε4 frequency was found to be 
around 4 times higher in AD groups than in control groups, reflecting the strong 
association proposed between this allele and AD pathology.  In our study, and despite the 
small size of the sample, this association between ApoE allele ε4 and AD was also evident, 
as it represents 25,0% of total alleles in that group. Interestingly, for the Aβ+ group the 
frequency of this allele was also 25,0%, which may indicate that individuals from this 
group have a greater propensity to develop AD pathology. On the other hand, ApoE allele 
ε4 was rarely detected in the OD group (with a frequency of 3,6%), suggesting that this 
allele strongly correlates with amyloid pathology development and less with other types 
of dementia. 
Our work entirely supports the acquired notion that ApoE allele ε4 is a major risk 
factor for AD, and less for other neurological diseases. Importantly, a very strong 
correlation was also obtained between ε4 allele and patients with amyloid pathology. As 
reported, the central role for ApoE allele ε4 in the modulation of processes of 
neurodegeneration, especially in amyloid pathology development, is probably associated 
with an isoform dependent effect on Aβ metabolism, aggregation and clearance from the 
brain (Castano et al., 1995; Polvikoski et al., 1995; Castellano et al., 2011; Bachmeier et 
al., 2012). Of note, according to Zetterberg et al. (2010), patients with altered Aβ levels 
(Aβ+ group) that progress in neurodegeneration can develop either AD or DLB. However, 
as ApoE ε4 is strongly linked to AD, we speculate that patients with amyloid pathology 
carrying the allele ε4 will most probably suffer from AD. A follow up study could clarify 
these aspects. 
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CONCLUDING REMARKS:  
 Of the six possible genotypes for ApoE gene, only four of them were observed: 
ε3ε3 (the more frequent), ε2ε3 (only in OD group), ε3ε4 (more frequent in AD and 
Aβ+ groups) and ε4ε4 (only in AD and Aβ+ groups). 
 Allele ε3 was the most frequent in all groups considered independently of the 
disease type, consistent with other population studies. 
 Allele ε2 was the less frequent allele, being only observed in OD group. This allele 
is associated with a protective role in AD development. 
 Allele ε4 was detected with a significantly higher frequency in the AD group than 
in the OD group. This supports ε4 allele as a major risk factor for AD development 
and less so for other neurological pathologies.  
 In Aβ+ group, allele ε4 frequency was similar to that of the AD group, suggesting 
that these individuals have an increased propensity to develop AD pathology. 
 In closing, the work carried out supports the notion that ApoE genetic testing 
should be considered as a useful adjunct diagnostic tool in clinical diagnosis of 
dementia, in particular to predict AD.  
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This section presents the equipment and composition of solutions used for the different 
techniques applied. 
7.1.1. Genomic DNA Extraction 
Equipment 
 Centrifuge 5417R (Eppendorf) 
 Thermomixer comfort (Eppendorf) 
Reagents 
 QIAamp DNA Blood Mini Kit (Qiagen)  
 RNase A (Sigma-Aldrich) 
7.1.2. Agarose Gel Electrophoresis 
Equipment 
 DNA electrophoresis system (Bio-Rad) 
 Power PAC300 (Bio-Rad) 
 AlphaImager HP System (Fisher Scientific) 
Reagents 
 Agarose  (Invitrogen) 
 Bromophenol Blue 
To 7 mL of deionized H2O add: 
- 0,025 g  bromophenol blue (0,25%) 
- 3 ml glycerol (30%) 
Mix and store at 4°C. 
 
 EtBr (10mg/ml) 
To 100 mL of deionized H2O add: 
- 1g EtBr 
Mix in a magnetic stirrer during several hours to ensure that the dye is 
totally dissolved. Wrap the tube with aluminum foil to maintain the 
solution protected from light.  
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 GreenSafe (nzytech) 
 0,5M Ethylenediamine tetra-acetic acid (EDTA) (pH 8.0) 
To 80 mL of deionized H2O add: 
- 14,612 g EDTA 
Mix until the solute has dissolved and adjust pH to 8.0 with NaOH. 
Adjust the volume to 100 ml with deionized H2O. Store at room 
temperature. 
 
 50X TAE (Tris-Acetate-EDTA Buffer)  
To 600 mL of deionized H2O add: 
- 242g Tris Base 
- 57,1 ml Glacial Acetic Acid 
- 100 ml 0,5M EDTA (pH 8.0) 
Mix until the solutes have dissolved and adjust the volume to 1L with 
deionized H2O. Store at room temperature. 
 
 10X TBE (Tris-Borate-EDTA Buffer) 
To 600 mL of deionized H2O add: 
- 108g Tris Base 
- 55g Boric Acid 
- 40ml 0,5M EDTA (pH 8.0) 
Mix until the solutes have dissolved and adjust the volume to 1L with 
deionized H2O. Store at room temperature. 
 
 1 kb plus DNA Ladder (Invitrogen) 
 10 bp DNA Ladder (Invitrogen) 
 
7.1.3. DNA concentration and purity 
Equipment 
 NanoDrop Spectrophotometer ND-1000 (Thermo Scientific) 
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7.1.4. PCR 
Equipment 
 My Cycler TM (Bio-Rad) 
 
Reagents 
 Primers (nzytech) 
- FW-CGGGCACGGCTGTCCAAGGAG 
- Rev-CTGGTGGAACAGGGCCGCGTG 
 Betaine (Sigma-Aldrich) 
 dNTPs 10mM (New England Biolabs) 
 KlenTaq LA DNA Polymerase Mix (Sigma-Aldrich) 
 10x PCR Buffer (Sigma-Aldrich) 
 
7.1.5. Enzymatic Restriction 
Reagents 
 HhaI (New England Biolabs) 
 10x NEBuffer4 (New England Biolabs) 
 100x BSA (New England Biolabs) 
